FR20C1054I1 - QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF THESE DERIVATIVES - Google Patents

QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF THESE DERIVATIVES

Info

Publication number
FR20C1054I1
FR20C1054I1 FR20C1054C FR20C1054C FR20C1054I1 FR 20C1054 I1 FR20C1054 I1 FR 20C1054I1 FR 20C1054 C FR20C1054 C FR 20C1054C FR 20C1054 C FR20C1054 C FR 20C1054C FR 20C1054 I1 FR20C1054 I1 FR 20C1054I1
Authority
FR
France
Prior art keywords
derivatives
pharmaceutical compositions
quinoline
quinoline derivatives
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1054C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613158A external-priority patent/GB0613158D0/en
Priority claimed from GB0613156A external-priority patent/GB0613156D0/en
Priority claimed from GB0613160A external-priority patent/GB0613160D0/en
Priority claimed from GB0613159A external-priority patent/GB0613159D0/en
Priority claimed from EP06117129A external-priority patent/EP1878722A1/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR20C1054I1 publication Critical patent/FR20C1054I1/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR20C1054C 2006-06-30 2020-11-12 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF THESE DERIVATIVES Active FR20C1054I1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0613158A GB0613158D0 (en) 2006-06-30 2006-06-30 Organic compounds
GB0613156A GB0613156D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613160A GB0613160D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613159A GB0613159D0 (en) 2006-06-30 2006-06-30 Organic Compounds
EP06117129A EP1878722A1 (en) 2006-07-13 2006-07-13 Quinolinone derivatives and their pharmaceutical compositions
EP07819899A EP2044025B1 (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions

Publications (1)

Publication Number Publication Date
FR20C1054I1 true FR20C1054I1 (en) 2020-12-25

Family

ID=38610531

Family Applications (2)

Application Number Title Priority Date Filing Date
FR20C1054C Active FR20C1054I1 (en) 2006-06-30 2020-11-12 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF THESE DERIVATIVES
FR20C1063C Active FR20C1063I1 (en) 2006-06-30 2020-12-08 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF THESE DERIVATIVES

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR20C1063C Active FR20C1063I1 (en) 2006-06-30 2020-12-08 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF THESE DERIVATIVES

Country Status (28)

Country Link
US (2) US8198450B2 (en)
EP (1) EP2044025B1 (en)
JP (1) JP5253392B2 (en)
KR (1) KR101402398B1 (en)
CN (1) CN101479245B (en)
AU (1) AU2007264946B2 (en)
BR (1) BRPI0713951B8 (en)
CA (1) CA2654801C (en)
CY (3) CY1113733T1 (en)
DK (1) DK2044025T3 (en)
ES (1) ES2396987T3 (en)
FR (2) FR20C1054I1 (en)
HK (1) HK1127597A1 (en)
HR (1) HRP20121074T1 (en)
HU (2) HUS2000043I1 (en)
IL (1) IL195796A (en)
LT (2) LTC2044025I2 (en)
LU (2) LUC00185I2 (en)
MA (1) MA30540B1 (en)
MX (1) MX2008016542A (en)
MY (1) MY150468A (en)
NO (3) NO341709B1 (en)
NZ (1) NZ573292A (en)
PL (1) PL2044025T3 (en)
PT (1) PT2044025E (en)
SI (1) SI2044025T1 (en)
WO (1) WO2008000839A1 (en)
ZA (1) ZA200809948B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
CA2697495C (en) * 2007-09-05 2013-02-05 Pfizer Limited Xinafoate salt of n4-[(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine
JOP20120023B1 (en) 2011-02-04 2022-03-14 Novartis Ag Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
WO2014141069A1 (en) 2013-03-14 2014-09-18 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
ES2747905T3 (en) 2015-09-29 2020-03-12 Inke Sa (R) -5- [2- (5,6-Diethylindan-2-ylamino) -1-hydroxyethyl] -8-hydroxy-1H-quinolin-2-one L-tartrate mixed solvate
CN110724095B (en) * 2019-09-12 2023-06-09 上海方予健康医药科技有限公司 Preparation method of indacaterol acetate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05202301A (en) * 1991-08-29 1993-08-10 Yamamoto Chem Inc Crystal modification of 2-anilino-3-methyl-6-@(3754/24)n-n-butyl-n-cyclohexylamino)fluoran, its production and recording material containing the same crystal modification
EP0688871A3 (en) * 1994-06-24 1998-07-08 Quest International B.V. Preparation of phytosphingosine derivative
FR2777279B1 (en) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc NEW CRYSTALLINE FORMS OF 1S- [1ALPHA (2S *, 3R *), 9 ALPHA] 6,10-DIOXO-N- (2-ETHOXY-5-OXO-TETRAHYDRO-3-FURANYL) -9 [[(1-ISOQUINOLYL ) CARBONYL] AMINO] OCTOHYDRO-6H-PYRIDAZINO [1,2-A] [1,2] DIAZEPINE-1-CARBOXAMIDE
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
US7417051B2 (en) * 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20100399A1 (en) 2003-04-02 2010-06-01 Novartis Ag PROCEDURE TO PREPARE OXY- (1H) -QUINOLIN-2-ONAS 5- (ALPHA-HALOACETIL) -8-SUBSTITUTED
ATE421322T1 (en) 2003-04-04 2009-02-15 Novartis Pharma Gmbh QUINOLIN-2-ONE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
JP2005343889A (en) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd Imidazopyridine derivative
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
PT1869049E (en) 2005-03-21 2009-05-26 Lilly Co Eli Imidazopyridazine compounds
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors

Also Published As

Publication number Publication date
LUC00188I2 (en) 2024-07-01
BRPI0713951B8 (en) 2021-05-25
LTPA2020538I1 (en) 2021-01-11
FR20C1063I1 (en) 2021-01-22
LTC2044025I2 (en) 2022-10-10
JP2009541455A (en) 2009-11-26
NO341709B1 (en) 2018-01-02
IL195796A0 (en) 2009-09-01
NO2020044I1 (en) 2020-12-07
JP5253392B2 (en) 2013-07-31
BRPI0713951A2 (en) 2012-12-04
ZA200809948B (en) 2009-05-25
HK1127597A1 (en) 2009-10-02
HRP20121074T1 (en) 2013-01-31
PL2044025T3 (en) 2013-02-28
SI2044025T1 (en) 2013-01-31
LUC00185I2 (en) 2024-07-01
KR20090023651A (en) 2009-03-05
BRPI0713951B1 (en) 2019-08-13
EP2044025A1 (en) 2009-04-08
CY1113733T1 (en) 2016-06-22
MY150468A (en) 2014-01-30
CN101479245B (en) 2013-05-22
CY2020038I1 (en) 2021-03-12
HUS2000053I1 (en) 2020-12-28
AU2007264946B2 (en) 2011-01-20
NZ573292A (en) 2011-03-31
WO2008000839A1 (en) 2008-01-03
CY2020041I2 (en) 2021-03-12
IL195796A (en) 2016-03-31
US20090325912A1 (en) 2009-12-31
AU2007264946A1 (en) 2008-01-03
CA2654801A1 (en) 2008-01-03
HUS2000043I1 (en) 2020-12-28
US20120316142A1 (en) 2012-12-13
MX2008016542A (en) 2009-01-19
CY2020041I1 (en) 2021-03-12
NO2020041I1 (en) 2020-11-23
US8198450B2 (en) 2012-06-12
CN101479245A (en) 2009-07-08
PT2044025E (en) 2012-12-17
DK2044025T3 (en) 2013-01-14
KR101402398B1 (en) 2014-06-03
MA30540B1 (en) 2009-06-01
EP2044025B1 (en) 2012-10-03
LTPA2020535I1 (en) 2020-12-28
CA2654801C (en) 2014-08-19
ES2396987T3 (en) 2013-03-01
CY2020038I2 (en) 2021-03-12
NO20090312L (en) 2009-01-28

Similar Documents

Publication Publication Date Title
FR20C1063I1 (en) QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF THESE DERIVATIVES
IL199853A (en) Substituted derivatives of 5-hydroxy-adamantyl-2-yl and pharmaceutical compositions comprising them
BRPI0918206A2 (en) animoester derivatives and medicinal composition of these
BRPI0923836A2 (en) Opioid-containing oral pharmaceutical compositions and methods
BRPI0906980A2 (en) Composition of derivatives and maleatados
SMT201700084B (en) ANTINEOPLASTIC ASSOCIATIONS OF 4-ANILINO-3-CIANOCHINOLINE AND CAPECITABINE
DE602007010981D1 (en) CYCLOALKYLAMINE-SUBSTITUTED ISOCHINOLINE AND ISOCHINOLINE DERIVATIVES
CR10815A (en) NEW DERIVATIVES OF ISOQUINOLIN AND ISOQUINOLINONA REPLACED
DOP2007000084A (en) DERIVATIVES OF DIHYDROPIRAZOLOPIRIMIDINONE
EP2188259A4 (en) Method of making and administering quinoline derivatives as anti-cancer agents
IL206594A (en) Azinone-tetrahydropyridoindole derivatives and pharmaceutical compositions comprising thereof
CR10229A (en) DERIVATIVES OF 1,2,4,5, -TETRAHIDRO-3H-BENZAZEPINAS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BRPI1007092A2 (en) "hydroxamate derivatives, use of hydroxamate derivatives, pharmaceutical compositions, method for disease prevention or treatment and method of production of hydroxamate derivatives"
IL193211A (en) Indazole-heteroaryl derivatives and pharmaceutical compositions comprising them
BRPI0813100A2 (en) PHARMACEUTICAL SOLID PREPARATION AND METHOD OF PRODUCTION
CR10809A (en) DERIVATIVES OF HETEROARIL-PIRROLIDINIL-Y-PIPERIDINIL-CETONA
ATE499368T1 (en) QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION
BRPI0922286A2 (en) quinolone compound and pharmaceutical composition.
BRPI0819202A2 (en) Heterocyclic Derivative and Pharmaceutical Composition
UY33128A (en) PIRIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF THE SAME
ZA200806725B (en) New citrate salt of an indole derivative and its pharmaceutical use
ATE465994T1 (en) ANTIBACTERIAL QUINOLINE DERIVATIVES
PL2220047T3 (en) Quinoline derivatives, pharmaceutical compositions comprising them, and use thereof
BRPI0812832A2 (en) PHARMACEUTICAL COMBINATION OF OPIOIDS AND PROSTAGLANDINE COMPOUND
TH0801002797A (en) Quinolone compounds and pharmaceutical components